This report provides comprehensive information on the therapeutic development for Raynauds Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Raynauds Disease and special features on late-stage and discontinued projects. http://www.researchmoz.us/raynauds-disease-pipeline-review-h1-2015-report.html

1. Raynauds Disease - Pipeline Review, H1 2015
Global Markets Directs, Raynauds Disease Pipeline Review, H1 2015, provides an overview of the Raynauds Diseases therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Raynauds Disease, complete with comparative analysis at various stages,
therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured
news and press releases. It also reviews key players involved in the therapeutic development for Raynauds Disease and special features on late-stage and
discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built
using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and
featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug
profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the
latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that
the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by
identifying new targets and MOAs to produce first-in-class and best-in-class products.
Scope
The report provides a snapshot of the global therapeutic landscape of Raynauds Disease The report reviews key pipeline products under drug profile section
which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key players
involved in the therapeutics development for Raynauds Disease and enlists all their major and minor projects The report summarizes all the dormant and
discontinued pipeline projects A review of the Raynauds Disease products under development by companies and universities/research institutes based on
information derived from company and industry-specific sources Pipeline products coverage based on various stages of development ranging from
pre-registration till discovery and undisclosed stages A detailed assessment of monotherapy and combination therapy pipeline projects Coverage of the Raynauds
Disease pipeline on the basis of target, MoA, route of administration and molecule type Latest news and deals relating related to pipeline products
Reasons to buy
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies Identify emerging players
with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Develop strategic initiatives by understanding the
focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Raynauds Disease Plan mergers and
acquisitions effectively by identifying key players of the most promising pipeline Devise corrective measures for pipeline projects by understanding Raynauds
Disease pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with
the most attractive projects to enhance and expand business potential and scope Modify the therapeutic portfolio by identifying discontinued projects and
understanding the factors that drove them from pipeline
table Of Contents
table Of Contents 2
list Of Tables 4
list Of Figures 5
introduction 6
global Markets Direct Report Coverage 6
raynauds Disease Overview 7
therapeutics Development 8
pipeline Products For Raynauds Disease - Overview 8
pipeline Products For Raynauds Disease - Comparative Analysis 9
raynauds Disease - Therapeutics Under Development By Companies 10
raynauds Disease - Therapeutics Under Investigation By Universities/institutes 11
raynauds Disease - Pipeline Products Glance 12
late Stage Products 12
clinical Stage Products 13
early Stage Products 14
raynauds Disease - Products Under Development By Companies 15
raynauds Disease - Products Under Investigation By Universities/institutes 16
raynauds Disease - Companies Involved In Therapeutics Development 17
allergan, Inc. 17
apricus Biosciences, Inc. 18
azevan Pharmaceuticals, Inc. 19
bayer Ag 20
human Stem Cells Institute 21
mezzion Pharma Co. Ltd. 22
nippon Shinyaku Co., Ltd. 23
teva Pharmaceutical Industries Limited 24
raynauds Disease - Therapeutics Assessment 25
assessment By Monotherapy Products 25
Raynauds Disease - Pipeline Review, H1 2015

2. assessment By Target 26
assessment By Mechanism Of Action 28
assessment By Route Of Administration 30
assessment By Molecule Type 32
drug Profiles 34
alprostadil - Drug Profile 34
product Description 34
mechanism Of Action 34
r&d Progress 34
els-140 - Drug Profile 37
product Description 37
mechanism Of Action 37
r&d Progress 37
gene Therapy To Activate Vascular Endothelial Growth Factor For Cardiovascular Disease And Central Nervous System Disorders - Drug Profile 38
product Description 38
mechanism Of Action 38
r&d Progress 38
mdt-012 - Drug Profile 39
product Description 39
mechanism Of Action 39
r&d Progress 39
onabotulinumtoxin A - Drug Profile 40
product Description 40
mechanism Of Action 40
r&d Progress 40
riociguat - Drug Profile 42
product Description 42
mechanism Of Action 42
r&d Progress 42
selexipag - Drug Profile 44
product Description 44
mechanism Of Action 44
r&d Progress 44
small Molecules To Inhibit Alpha 2 Adrenergic Receptor For Raynauds Disease - Drug Profile 46
product Description 46
mechanism Of Action 46
r&d Progress 46
srx-251 - Drug Profile 47
product Description 47
mechanism Of Action 47
r&d Progress 47
udenafil - Drug Profile 49
product Description 49
mechanism Of Action 49
r&d Progress 49
raynauds Disease - Recent Pipeline Updates 51
raynauds Disease - Dormant Projects 66
raynauds Disease - Discontinued Products 67
raynauds Disease - Product Development Milestones 68
featured News & Press Releases 68
jan 27, 2015: Apricus Biosciences Announces Issuance Of U.s. Patent For Rayva 68
dec 04, 2014: Apricus Biosciences Announces First Patient Enrolled In Phase 2a Clinical Trial For Rayva In Patients With Raynaud's Phenomenon 68
oct 13, 2014: Apricus Biosciences Announces Notice Of Allowance Of U.s. Patent Application For Rayva 69
oct 01, 2014: Apricus Biosciences To Present At The 13th Annual Bio Investor Forum 70
may 12, 2014: Apricus Biosciences Receives Fda Clearance To Begin Clinical Trial Of Rayva For Secondary Raynaud's Phenomenon 70
may 31, 2011: Apricus Bio Receives Israeli Patent For Rayva For Raynaud's Phenomenon 71
apr 13, 2011: Apricus Bio Files For Orphan Drug Designation For Rayva 71
sep 22, 2010: Fda Guides Apricus Bio On Rayva's Approvability For Raynaud's Syndrome Secondary To Scleroderma 72
appendix 73
methodology 73
coverage 73
secondary Research 73
primary Research 73
expert Panel Validation 73
contact Us 73
disclaimer 74
Raynauds Disease - Pipeline Review, H1 2015

3. ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your
research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and
across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an
informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact:
Sales Team,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Raynauds Disease - Pipeline Review, H1 2015